Market Overview

Arrowhead Research Soars After Acquiring Novartis' RNAi Portfolio

Related ARWR
Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading
Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares
Arrowhead Pharmaceuticals - Pullbacks Are Becoming Rare, So Take Advantage If You Love The Potential (Seeking Alpha)

Arrowhead Research Corp (NASDAQ: ARWR) was trading higher on Thursday after the announcement that it acquired Novartis' (NYSE: NVS) entire RNAi research and development portfolio.

According to Street Insider, "Novartis has been working in the RNAi field for over a decade and their developments in proprietary oligonucleotide formatting and modifications are some of the best we've seen. We anticipate this acquisition will provide us with substantially expanded freedom to operate, proprietary technology that appears to enhance the activity of RNAi triggers, access to non-delivery Alnylam RNAi IP for 30 targets, and three programs that went through the rigorous Novartis vetting process," said Christopher Anzalone, Ph.D., President and Chief Executive Officer of Arrowhead Research.

Arrowhead was particularly interested in Novartis's pipeline of three candidates that have developed pre-clinical data.

Arrowhead will pay Novartis $10 million in cash as $25 million in common stock.

Shares of Arrowhead Research recently traded at $7.80, up 3.8 percent.

Posted-In: News Small Cap M&A


Related Articles (ARWR + NVS)

View Comments and Join the Discussion!